Merck, Inc.
A Study of MK-1084 Human Absorption, Distribution, Metabolism, and Excretion in Healthy Adult Participants (MK-1084-006)
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8
- Registration Number
- NCT06687759
- Locations
- 🇺🇸
Fortea CRU Madison (Site 0001), Madison, Wisconsin, United States
A Study of the Effects of Itraconazole on the Plasma Levels of Nemtabrutinib (MK-1026-013)
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT06688045
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc. (Site 0001), Honolulu, Hawaii, United States
A Trial to Evaluate Tolerability and Immunogenicity of V540D in Healthy Adults (V540D-004)
- First Posted Date
- 2024-11-14
- Last Posted Date
- 2025-05-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT06688058
- Locations
- 🇺🇸
Alliance for Multispecialty Research, LLC ( Site 0003), Kansas City, Missouri, United States
🇺🇸Alliance for Multispecialty Research, LLC ( Site 0004), Knoxville, Tennessee, United States
🇺🇸Velocity Clinical Research, Savannah ( Site 0005), Savannah, Georgia, United States
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
- Conditions
- Breast NeoplasmsBreast Cancer
- Interventions
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 81
- Registration Number
- NCT06686394
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey ( Site 0052), New Brunswick, New Jersey, United States
🇺🇸Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053), Greenville, South Carolina, United States
🇮🇱Rambam Health Care Campus ( Site 0011), Haifa, Israel
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Drug: MolnupiravirDrug: Placebo
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-05-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3082
- Registration Number
- NCT06667700
- Locations
- 🇯🇵
Tsuchiura Beryl Clinic ( Site 2009), Tsuchiura, Ibaraki, Japan
🇯🇵Kumamoto Chuo Hospital ( Site 2002), Kumamoto, Japan
🇺🇸Cullman Clinical Trials ( Site 3813), Cullman, Alabama, United States
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 160
- Registration Number
- NCT06664801
- Locations
- 🇩🇪
Universitaetsklinikum Hamburg-Eppendorf ( Site 0610), Hamburg, Germany
🇯🇵National Hospital Organization Okayama Medical Center ( Site 2104), Okayama, Japan
🇺🇸Pulmonary Associates, PA ( Site 1903), Phoenix, Arizona, United States
A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005)
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT06665230
- Locations
- 🇺🇸
Alliance for Multispecialty Research, LLC (Site 0001), Knoxville, Tennessee, United States
A Study of Diltiazem With a Single Dose of MK-6552 in Healthy Adult Participants (MK-6552-007)
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT06662396
- Locations
- 🇺🇸
ICON (Site 0001), Lenexa, Kansas, United States
A Study to Evaluate the Metabolism, Excretion, and Mass Balance of [¹⁴C]Enlicitide Chloride ([¹⁴C]MK-0616) in Healthy Participants (MK-0616-016)
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 8
- Registration Number
- NCT06658626
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc. (Site 0001), Madison, Wisconsin, United States
The Effect of Food and Water Volume in Healthy Adult Participants Administered Enlicitide Decanoate (MK-0616) (MK-0616-022)
- First Posted Date
- 2024-10-26
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 34
- Registration Number
- NCT06658652
- Locations
- 🇺🇸
Celerion (Site 0001), Lincoln, Nebraska, United States